Research team

Expertise

Annelies Mondelaers is a researcher at the Global Health Institute of the University of Antwerp, where she is part of the team led by Prof. Dr. Erika Vlieghe. In this role, she is responsible for the management and coordination of various research projects on infectious diseases, with a particular focus on high consequence infectious diseases, pandemic preparedness, and public health. Within the FiLi-Vi-X project, she develops, organizes, and implements training programs for primary healthcare workers, aimed at better preparing them for future pandemics. In addition, she is actively involved in projects related to crisis preparedness, CBRN defense, and crisis communication. She develops innovative research lines and supervises projects from concept to implementation and valorization. Besides her research activities, Annelies Mondelaers also serves as the academic coordinator of the High-Level Isolation Unit (HLIU) at the University Hospital of Antwerp (UZA), where she leads a team of two nurses. In this capacity, she co-organizes simulation exercises with both national and international partners. She collaborates closely with various departments within both the University of Antwerp and the University Hospital Antwerp. Externally, she maintains partnerships with health authorities, university partners, and professional associations such as Domus Medica and the Flemish Association of Emergency Care Nurses (VVVS), as well as with the Port of Bruges-Antwerp, the City of Antwerp, colleges, the Academy for Primary Care, VIVEL, the National Crisis Center, and the Belgian Defense.

Induction of miltefosine (MIL)-resistance on Leishmania amastigotes: study of the effect of resistance on MIL-internalisation, processing and parasitic fitness. 01/01/2013 - 31/12/2016

Abstract

Visceral leishmaniasis (VL) is caused by Leishmania donovani and L. infantum. Current drug therapies are associated with resistance, a high cost price, parenteral administration or serious side effects. Miltefosine (MIL) is the first oral drug against VL with a good therapeutic effect and ease of use and an acceptable safety profile. Recently, MIL was positioned as first-line therapy in India, Nepal and Bangladesh. However, MIL shows some characteristics that promote the emergence of resistance. The selection of MIL-resistant strains should be prevented and monitored, especially since there are no alternative drugs in clinical development. To proactively address the development of MIL-resistance, research on the resistance mechanisms and their cell biological and clinical implications is very important. This research project aims to obtain a standardized, clinically relevant laboratory model for the experimental induction of MIL-resistance. The MIL-resistant strains will be used to evaluate the effect of resistance on the MIL-uptake and parasite-cell interaction in Leishmania-infected macrophages. In addition, the fitness of the resistant strains will be assessed.

Researcher(s)

Research team(s)

Project type(s)

  • Research Project